Skip to main content

Table 4 Odds ratios (ORs) and 95% confidence intervals (CIs) for a doubling in hormone concentration for all women and according to subject characteristicsa

From: Premenopausal serum androgens and breast cancer risk: a nested case-control study

Characteristic

Hormone

(number of cases)

Testosterone

Free Testosterone

Androstenedione

DHEAS

SHBG

All women (n = 354)

     

   OR (95% CI)

1.6 (1.2, 2.3)

1.3 (1.1, 1.5)

1.3 (1.0, 1.7)

1.1 (0.9, 1.4)

0.9 (0.8, 1.1)

   P-value

0.01

0.003

0.07

0.31

0.47

Tumor type

     

   Invasive (n = 274)

     

OR (95% CI)

1.5 (1.1, 2.2)

1.2 (1.0, 1.4)

1.3 (0.9, 1.8)

1.1 (0.8, 1.4)

1.0 (0.8, 1.2)

P-value

0.03

0.02

0.11

0.60

0.84

   In situ (n = 80)

     

OR (95% CI)

2.3 (0.9, 5.9)

1.4 (1.0, 2.1)

2.0 (0.9, 4.5)

1.6 (0.9, 2.8)

0.8 (0.5, 1.3)

P-value

0.09

0.07

0.10

0.14

0.37

Estrogen receptor statusb

     

   Positive (n = 104)

     

OR (95% CI)

2.4 (1.2, 4.6)

1.6 (1.2, 2.2)

2.2 (1.3, 3.8)

1.2 (0.8, 1.8)

0.9 (0.6, 1.3)

P-value

0.01

0.003

0.01

0.42

0.56

   Negative (n = 60)

     

OR (95% CI)

1.7 (0.7, 4.3)

1.2 (0.9, 1.8)

0.7 (0.3, 1.6)

1.4 (0.7, 2.6)

0.8 (0.5, 1.4)

P-value

0.25

0.26

0.37

0.34

0.41

Age at enrollmentc

     

   < 40 yrs (n = 77)

     

OR (95% CI)

1.7 (0.7, 4.2)

1.3 (0.9, 2.0)

1.3 (0.6, 2.7)

0.9 (0.5, 1.5)

0.7 (0.4, 1.2)

P-value

0.27

0.19

0.45

0.61

0.17

   40- to yrs (n = 117)

     

OR (95% CI)

1.4 (0.7, 2.6)

1.1 (0.8, 1.4)

1.1 (0.7, 1.8)

1.1 (0.8, 1.6)

1.2 (0.8, 1.8)

P-value

0.33

0.50

0.72

0.53

0.36

   ≥45 yrs (n = 160)

     

OR (95% CI)

1.9 (1.2, 3.2)

1.4 (1.1, 1.7)

1.5 (1.0, 2.3)

1.2 (0.9, 1.7)

0.9 (0.7, 1.2)

P-value

0.01

0.004

0.08

0.21

0.57

Menopausal status at diagnosisd, e

     

   Pre (n = 152)

     

OR (95% CI)

1.4 (0.8, 2.3)

1.1 (0.9, 1.4)

1.0 (0.7, 1.5)

1.1 (0.8, 2.5)

1.0 (0.8, 1.4)

P-value

0.23

0.36

0.98

0.56

0.80

   Post (n = 161)

     

OR (95% CI)

1.7 (1.1, 2.6)

1.3 (1.1, 1.6)

1.3 (0.9, 1.9)

1.2 (0.8, 1.6)

0.9 (0.7, 1.1)

P-value

0.02

0.006

0.18

0.39

0.26

BMId

     

   < 25 kg/m2 (n = 239)

     

OR (95% CI)

1.8 (1.2, 2.6)

1.3 (1.1, 1.5)

1.2 (0.9, 1.6)

1.3 (1.0, 1.6)

0.9 (0.7, 1.1)

P-value

0.003

0.003

0.30

0.08

0.41

25 to 29.9 kg/m2 (n = 74)

     

OR (95% CI)

2.4 (1.1, 5.0)

1.5 (1.1, 2.1)

1.9 (1.0, 3.5)

1.3 (0.8, 2.1)

1.1 (0.8, 1.7)

P-value

0.02

0.01

0.05

0.29

0.58

≥30 kg/m2 (n = 108)

     

OR (95% CI)

1.5 (0.8, 2.7)

1.2 (0.9, 1.6)

1.6 (1.0, 2.5)

1.0 (0.7, 1.5)

1.1 (0.8, 1.5)

P-value

0.20

0.11

0.08

0.95

0.64

Lag time between blood donation and diagnosisf

     

   < 7 yrs (n = 154)

     

OR (95% CI)

2.0 (1.1, 3.5)

1.3 (1.0, 1.7)

1.3 (0.9, 2.1)

1.4 (1.0, 1.9)

1.0 (0.8, 1.5)

P-value

0.02

0.04

0.20

0.06

0.78

   ≥7 yrs (n = 200)

     

OR (95% CI)

1.5 (1.0, 2.3)

1.3 (1.0, 1.5)

1.3 (0.9, 1.9)

1.0 (0.7, 1.3)

0.8 (0.6, 1.1)

P-value

0.07

0.02

0.17

0.80

0.22

5 to7 cycles in 6 months prior to enrollment and regular cyclesd (n = 253)

     

OR (95% CI)

1.6 (1.1, 2.3)

1.2 (1.1, 1.5)

1.3 (1.0, 1.8)

1.1 (0.9, 1.5)

0.9 (0.8, 1.2)

P-value

0.02

0.01

0.07

0.29

0.59

  1. aAdjusted for age at menarche (< 12, 12, 13, > 13, missing), family history of breast cancer (no, one affected first-degree relative > 45 yrs old, one affected first degree relative < 45 yrs old or more than one affected first-degree relative), parity/age at first birth (≤20 years at first full-term pregnancy, 21 to 25 years at first full-term pregnancy, 26 to 30 years at first full-term pregnancy, > 30 years at first full-term pregnancy, nulliparous, missing), history of breast biopsy, and body mass index (< 20, 20-22.5, 22.6-24.9, 25-29.9, 30+, missing). b0.05 <Pinteraction < 0.15 for androstenedione. c0.05 <Pinteraction < 0.15 for free testosterone. dUsing unconditional logistic regression, adjusting for matching factors in addition to factors listed in a. e 0.05 <Pinteraction < 0.15 for free testosterone. f0.05 <Pinteraction < 0.15 for SHBG. DHEAS, dehydroandrosterone sulfate; SHBG, sex hormone-binding globulin.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us